Chemocentryx reported $5.46M in Sales Revenues for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
Abbvie ABBV:US $ 13538M 1348M
Alnylam Pharmaceuticals ALNY:US $ 213.26M 45.28M
Amgen AMGN:US $ 6238M 608M
AstraZeneca AZN:LN 11390M 621M
Bayer BAYN:GR € 14639M 3521M
Biogen BIIB:US $ 2531.8M 202M
Biomarin Pharmaceutical BMRN:US $ 519.36M 69.55M
Bristol Myers Squibb BMY:US $ 11648M 337M
Chemocentryx CCXI:US $ 5.46M 3.14M
Glaxosmithkline GSK:US $ 9780M 253M
Merk MRK:US $ 15901M 2380M
Mirati Therapeutics MRTX:US $ 0.71M 0.41M
Novartis NOVN:VX SF 12814M 708M
Takeda 4502:JP Y 873289M 28005M
Teva Pharmaceutical TEVA:IT 3.66B 439M